Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

Samankaltaisia teoksia

• Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)
  Tekijä: Zang, Hongjing, et al.
  Julkaistu: (2020)
• ERK inhibition effectively overcomes acquired resistance of EGFR-mutant NSCLC cells to osimertinib
  Tekijä: Li, Yiting, et al.
  Julkaistu: (2019)
• Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
  Tekijä: Gu, Jiajia, et al.
  Julkaistu: (2020)
• MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of EGFR-mutant lung cancers
  Tekijä: Gu, Jiajia, et al.
  Julkaistu: (2020)
• Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
  Tekijä: La Monica, Silvia, et al.
  Julkaistu: (2017)